Vallières Eric
Division of Cardiothoracic Surgery, University of Washington, Seattle 98195, USA.
Semin Thorac Cardiovasc Surg. 2003 Oct;15(4):431-7. doi: 10.1053/s1043-0679(03)00096-0.
More than 50% of patients presenting with so-called early stage or surgical disease nonsmall-cell lung cancer will die of their cancer despite resection. Over the years, postoperative efforts to improve the survival of these patients have been disappointing. There is presently a lot of enthusiasm surrounding the strategy of preoperative or induction chemotherapy in the treatment of such patients. Worldwide, at least 4 large-scale ongoing cooperative group trials are evaluating this question at the present time. Only by completing these trials in a timely manner will we know if induction chemotherapy should become the standard of care for all patients with surgical disease nonsmall-cell lung cancer.
超过50%表现为所谓早期或可手术的非小细胞肺癌患者，即便接受了手术切除，仍会死于癌症。多年来，术后为提高这些患者生存率所做的努力一直令人失望。目前，对于此类患者的治疗，术前或诱导化疗策略备受关注。目前全球至少有4项大规模正在进行的合作组试验在评估这一问题。只有及时完成这些试验，我们才能知道诱导化疗是否应成为所有可手术的非小细胞肺癌患者的标准治疗方案。
